Business Context and Reporting Period
Prestige Consumer Healthcare Inc. (PBH) filed a Form 8-K on March 19, 2026, reporting the entry into a Material Definitive Agreement. The filing details a strategic acquisition intended to expand the company's portfolio of over-the-counter consumer health products.
Key Financial Metrics and Transaction Details
- Transaction Value: $1.045 billion in cash.
- Target Assets: A portfolio of over-the-counter consumer health products from Foundation Consumer Brands, LLC, including the Breathe Right® brand.
- Acquiring Entity: Prestige Brands, Inc., a wholly-owned subsidiary of Prestige Consumer Healthcare Inc.
- Financial Impact: The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity metrics for the company or the target assets.
Material Changes and Transaction Timeline
The primary material change is the execution of the Asset Purchase Agreement. The transaction is expected to close in the first half of Fiscal 2027, subject to customary closing conditions and clearance under the Hart-Scott Rodino Antitrust Improvements Act of 1976. The agreement includes a termination right if the transaction does not close prior to July 20, 2026.
Outlook, Risks, and Management Commentary
- Management Commentary: The Company began investor presentations on March 19, 2026, utilizing an attached Investor Presentation (Exhibit 99.1) to discuss the transaction.
- Risks and Contingencies: Closing is contingent on regulatory approval and satisfaction of customary conditions. The agreement includes standard termination rights for breach of contract or failure to meet closing conditions.
- Legal Protections: The Purchaser has obtained representation and warranty insurance as its sole recourse for losses related to breaches of representations and warranties, excluding fraud.
- Unusual Items: None reported in this filing.
Investor Verification Checklist
- Verify the final closing date and confirm receipt of Hart-Scott Rodino antitrust clearance.
- Review the full Asset Purchase Agreement (expected in the Form 10-K for the year ending March 31, 2026) for detailed representations and warranties.
- Assess the Company's liquidity and capital resources to fund the $1.045 billion cash purchase.
- Monitor for any updates regarding the termination date of July 20, 2026.